Guggenheim Has Lowered Expectations for Urogen Pharma (NASDAQ:URGN) Stock Price

Urogen Pharma (NASDAQ:URGN) had its price objective lowered by analysts at Guggenheim from $58.00 to $56.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim‘s target price would suggest a potential upside of 109.32% from the company’s current price.

Several other research analysts also recently commented on the company. TD Cowen raised their price objective on Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. UBS Group reaffirmed an “outperform” rating on shares of Urogen Pharma in a report on Thursday. The Goldman Sachs Group reissued a “neutral” rating and issued a $44.00 price objective on shares of Urogen Pharma in a report on Wednesday, July 15th. Oppenheimer set a $60.00 target price on shares of Urogen Pharma in a research note on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Thursday, October 15th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.38.

Urogen Pharma Price Performance

URGN traded down $1.99 on Thursday, hitting $26.75. The company had a trading volume of 626,533 shares, compared to its average volume of 848,285. The firm has a market capitalization of $1.31 billion, a P/E ratio of -13.46 and a beta of 1.68. The stock has a fifty day simple moving average of $39.60 and a 200-day simple moving average of $31.46. Urogen Pharma has a 52-week low of $16.50 and a 52-week high of $50.81.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.14). The company had revenue of $89.00 million during the quarter, compared to the consensus estimate of $89.92 million. Equities research analysts expect that Urogen Pharma will post -0.20 earnings per share for the current fiscal year.

Insider Transactions at Urogen Pharma

In other Urogen Pharma news, CFO Chris Degnan sold 2,202 shares of the firm’s stock in a transaction on Thursday, October 8th. The stock was sold at an average price of $36.69, for a total value of $80,791.38. Following the sale, the chief financial officer directly owned 4,561 shares in the company, valued at approximately $167,343.09. This trade represents a 32.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel Jason Smith sold 1,519 shares of Urogen Pharma stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $42.54, for a total transaction of $64,618.26. Following the completion of the sale, the general counsel owned 53,141 shares in the company, valued at approximately $2,260,618.14. This represents a 2.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 65,269 shares of company stock worth $3,037,646. 4.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Urogen Pharma

Several large investors have recently made changes to their positions in URGN. CenterBook Partners LP bought a new stake in Urogen Pharma during the third quarter worth approximately $642,000. Calamos Advisors LLC bought a new position in Urogen Pharma during the 3rd quarter valued at $246,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Urogen Pharma during the 3rd quarter valued at $101,000. State of Wyoming boosted its stake in Urogen Pharma by 773.4% during the 3rd quarter. State of Wyoming now owns 4,629 shares of the company’s stock valued at $188,000 after purchasing an additional 4,099 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Urogen Pharma by 15.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,919 shares of the company’s stock valued at $361,000 after purchasing an additional 1,165 shares during the period. Institutional investors and hedge funds own 91.29% of the company’s stock.

Urogen Pharma News Roundup

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: ZUSDURI generated $68 million in third-quarter revenue, up 35% from the prior quarter. The company also said repeat prescribers now make up half of ZUSDURI writers, pointing to continued commercial adoption. The Gel That Became a Business
• Positive Sentiment: The FDA accepted UroGen’s application for UGN-103, its next-generation mitomycin formulation, and set a June 14, 2027 target decision date. UroGen Q3 results and highlights
• Neutral Sentiment: UroGen reported that the first patient had been dosed in its UGN-501 Phase 1 trial, an early-stage pipeline development with no efficacy data yet. UroGen Q3 results and highlights
• Negative Sentiment: Quarterly revenue was about $89 million, slightly below analyst estimates, while the reported loss of $0.03 per share missed the consensus estimate cited in the provided coverage. The loss was narrower than a year earlier, but UroGen also cut its FY2026 guidance, raising concerns about near-term performance. UroGen stock falls on Q3 results and guidance cut

About Urogen Pharma

UroGen Pharma Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.